ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.

Tianxing ZhouJing LiuYongjie XieShuai YuanYu GuoWeiwei BaiKaili ZhaoWenna JiangHongwei WangHaotian WangTiansuo ZhaoChongbiao HuangSong GaoXiuchao WangShengyu YangBaocun Sun

Published in: Gut (2021)

EHF decreased the sensitivity of PC to the stimulus from PSC-derived CSC-supportive niche by negatively regulating tumorous CXCR4. Rosiglitazone could be used to target PC stem cells and the crosstalk between CSCs and their niche by upregulating EHF.

Keyphrases

stem cells
cell migration
cancer stem cells
signaling pathway
epithelial mesenchymal transition
cell therapy
bone marrow